An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...
Mar 21, 2018
0
1420
Almost all liver cancers develop after decades of chronic liver disease, but a new discovery by Columbia researchers may lead to treatments that could break the link.
Oct 21, 2022
0
478
In recent years, the immunotherapy field has revolutionized oncology treatment methods by developing therapeutics that help a cancer patient's own immune system fight their disease. However, these treatments have had varied ...
May 16, 2022
0
4
As main component of essential oils, terpenes can inhibit the growth of different cancer cells. Researchers from the Ruhr-University Bochum headed by Prof Dr Dr Dr Hanns Hatt have analysed this process in liver cancer cells ...
Jan 19, 2015
0
199
Hepatocellular carcinoma is the most common form of liver cancer, but treatment options are limited and many patients are diagnosed in late stages when the disease can't be treated. Now, University of Missouri School of Medicine ...
Feb 28, 2017
0
1
Two independent national studies have reported high rates of liver disease progression and mortality among patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH). The studies reported today ...
Apr 11, 2019
0
2
(HealthDay)—For patients with hepatitis C virus (HCV), statin therapy is associated with improved virologic response rates, as well as decreased liver fibrosis progression and hepatocellular carcinoma (HCC) incidence, according ...
Apr 10, 2015
0
63
Experts from Cedars-Sinai Cancer have analyzed patient samples, along with studies conducted in animal models, to identify a novel immune checkpoint pathway to treat hepatocellular carcinoma, the most common form of liver ...
Jun 20, 2022
0
108
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. In Germany, there are currently around 9,000 new HCC diagnoses per year, and almost 8,000 people affected do not survive the disease. Before the ...
Oct 19, 2022
0
57
Cancer metastasis is a major cause of cancer-related death. A research team at City University of Hong Kong (CityU) recently identified a protein that triggers the migration of liver and pancreatic cancer cells and metastasis ...
Mar 9, 2023
0
32
Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the most common type of liver cancer. Most cases of HCC are secondary to either a viral hepatitide infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).
Compared to other cancers, HCC is quite a rare tumor in the United States. In countries where hepatitis is not endemic, most malignant cancers in the liver are not primary HCC but metastasis (spread) of cancer from elsewhere in the body, e.g., the colon. Treatment options of HCC and prognosis are dependent on many factors but especially on tumor size and staging. Tumor grade is also important. High-grade tumors will have a poor prognosis, while low-grade tumors may go unnoticed for many years, as is the case in many other organs, such as the breast, where a ductal carcinoma in situ (or a lobular carcinoma in situ) may be present without any clinical signs and without correlate on routine imaging tests, although in some occasions it may be detected on more specialized imaging studies like MR mammography.
This text uses material from Wikipedia licensed under CC BY-SA
